β2-Microglobulin in monoclonal gammopathies

D. Vercelli, F. Cozzolino, A. Becucci, R. Di Guglielmo

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Serum β2m concentrations were evaluated in 130 samples from 77 patients with monoclonal gammopathies (42 multiple myelomas, 35 benign monoclonal gammopathies). A highly significant correlation (P < 0.001) was found between serum β2m and cell mass; mean serum β2m levels were statistically different in the three myeloma stages (P values ranging from P < 0.05 to P < 0.001). When benign monoclonal gammopathies and multiple myelomas were globally compared, mean β2m concentrations were significantly different (P < 0.001), but multiple comparisons showed that no difference existed between benign monoclonal gammopathies and low cell mass (stage I) myelomas. Serum β2m determinations are therefore not clinically useful for the differential diagnosis of monoclonal gammopathies.

Original languageEnglish (US)
Pages (from-to)85-88
Number of pages4
JournalNouvelle Revue Francaise d'Hematologie
Volume24
Issue number2
StatePublished - Jan 1 1982
Externally publishedYes

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'β<sub>2</sub>-Microglobulin in monoclonal gammopathies'. Together they form a unique fingerprint.

  • Cite this

    Vercelli, D., Cozzolino, F., Becucci, A., & Di Guglielmo, R. (1982). β2-Microglobulin in monoclonal gammopathies. Nouvelle Revue Francaise d'Hematologie, 24(2), 85-88.